In 2024, the ataxia market was valued at USD 37.70 billion. With growing research and drug approvals, this market is projected to expand at a 9.72% C ...

Biogen’s 4 nominations in the Pharma category for its Friedreich’s ataxia work included 3 in the “direct-to-patient ads for products or services” category and one in the “disease ...

Ajovy shows sustained two-year efficacy: Final PEARL Phase IV results confirm fremanezumab’s long-term effectiveness in preventing both chronic and episodic migraine. High adherence and safety ...

Despite their different causes, all forms of ataxia share a common set of motor impairments—specifically, a loss of motor rhythm and precision.

The authors describe three siblings with ataxia with oculomotor apraxia type 1 born to consanguineous parents.

Biogen has started a new phase 3 trial that aims to extend the use of its Friedreich's ataxia drug Skyclarys to patients as young as two.